Quick Answer
Bioventus Inc. reported Cash and Equivalents of $51.24 million for fiscal year 2025.
Bioventus Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $51.24M | +23.2% |
| 2024 | $41.58M | +12.5% |
| 2023 | $36.96M | +22.5% |
| 2022 | $30.19M | -31.3% |
| 2021 | $43.93M | -49.4% |
| 2020 | $86.84M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $42.16M | -2.1% | +28.1% |
| June 30, 2025 | $32.91M | +2.9% | +44.3% |
| March 31, 2025 | $22.80M | -9.4% | -45.2% |
| December 31, 2024 | $41.58M | +12.5% | -3.5% |
| September 30, 2024 | $43.07M | +60.6% | +34.6% |
| June 30, 2024 | $31.99M | +8.9% | +27.1% |
| March 31, 2024 | $25.17M | -46.6% | -31.9% |
| December 31, 2023 | $36.96M | +22.5% | +37.8% |
- Bioventus Inc. showed an increase of +23.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Bioventus Inc.’s cash and equivalents has declined by 41.0% (from $86.84 million to $51.24 million).
- The most recent figure is from Bioventus Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: